Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Determination of eumelanin and pheomelanin in melanomas using solid-phase extraction and high performance liquid chromatography-diode array detection (HPLC-DAD) analysis.

Rioux B, Rouanet J, Akil H, Besse S, Debiton E, Bouchon B, Degoul F, Quintana M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 15;1113:60-68. doi: 10.1016/j.jchromb.2019.03.010. Epub 2019 Mar 11.

PMID:
30897406
2.

Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029.

Bonnet M, Maisonial-Besset A, Zhu Y, Witkowski T, Roche G, Boucheix C, Greco C, Degoul F.

Cancers (Basel). 2019 Feb 3;11(2). pii: E179. doi: 10.3390/cancers11020179. Review.

3.

TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer.

Judes G, Dubois L, Rifaï K, Idrissou M, Mishellany F, Pajon A, Besse S, Daures M, Degoul F, Bignon YJ, Penault-Llorca F, Bernard-Gallon D.

Epigenomics. 2018 Nov;10(11):1415-1430. doi: 10.2217/epi-2018-0004. Epub 2018 Oct 16.

PMID:
30324811
4.

Radiation dosimetry of [131 I]ICF01012 in rabbits: Application to targeted radionuclide therapy for human melanoma treatment.

Jouberton E, Perrot Y, Dirat B, Billoux T, Auzeloux P, Cachin F, Chezal JM, Filaire M, Labarre P, Miot-Noirault E, Millardet C, Valla C, Vidal A, Degoul F, Maigne L.

Med Phys. 2018 Nov;45(11):5251-5262. doi: 10.1002/mp.13165. Epub 2018 Sep 24.

PMID:
30179267
5.

Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.

Voissiere A, Weber V, Gerard Y, Rédini F, Raes F, Chezal JM, Degoul F, Peyrode C, Miot-Noirault E.

Oncotarget. 2017 Sep 27;8(56):95824-95840. doi: 10.18632/oncotarget.21337. eCollection 2017 Nov 10.

6.

Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models.

Rondon A, Ty N, Bequignat JB, Quintana M, Briat A, Witkowski T, Bouchon B, Boucheix C, Miot-Noirault E, Pouget JP, Chezal JM, Navarro-Teulon I, Moreau E, Degoul F.

Sci Rep. 2017 Nov 2;7(1):14918. doi: 10.1038/s41598-017-15051-y.

7.

Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma.

Miladi I, Vivier M, Dauplat MM, Chatard M, Besse S, Vidal A, Chassain K, Jean B, Forestier C, Chezal JM, Rédini F, Degoul F, Miot-Noirault E.

Cancer Chemother Pharmacol. 2017 Sep;80(3):517-526. doi: 10.1007/s00280-017-3377-7. Epub 2017 Jul 13.

PMID:
28707014
8.

Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.

Voissiere A, Jouberton E, Maubert E, Degoul F, Peyrode C, Chezal JM, Miot-Noirault É.

PLoS One. 2017 Jul 13;12(7):e0181340. doi: 10.1371/journal.pone.0181340. eCollection 2017.

9.

Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.

Maisonial-Besset A, Witkowski T, Navarro-Teulon I, Berthier-Vergnes O, Fois G, Zhu Y, Besse S, Bawa O, Briat A, Quintana M, Pichard A, Bonnet M, Rubinstein E, Pouget JP, Opolon P, Maigne L, Miot-Noirault E, Chezal JM, Boucheix C, Degoul F.

Oncotarget. 2017 Mar 28;8(13):22034-22047. doi: 10.18632/oncotarget.15787.

10.

Tetraspanin 8 is a novel regulator of ILK-driven β1 integrin adhesion and signaling in invasive melanoma cells.

El Kharbili M, Robert C, Witkowski T, Danty-Berger E, Barbollat-Boutrand L, Masse I, Gadot N, de la Fouchardière A, McDonald PC, Dedhar S, Le Naour F, Degoul F, Berthier-Vergnes O.

Oncotarget. 2017 Mar 7;8(10):17140-17155. doi: 10.18632/oncotarget.15084.

11.

Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.

Rbah-Vidal L, Vidal A, Billaud EM, Besse S, Ranchon-Cole I, Mishellany F, Perrot Y, Maigne L, Moins N, Guerquin-Kern JL, Degoul F, Chezal JM, Auzeloux P, Miot-Noirault E.

Neoplasia. 2017 Jan;19(1):17-27. doi: 10.1016/j.neo.2016.11.001. Epub 2016 Dec 14.

12.

Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept.

Peyrode C, Weber V, Voissière A, Maisonial-Besset A, Vidal A, Auzeloux P, Gaumet V, Borel M, Dauplat MM, Quintana M, Degoul F, Rédini F, Chezal JM, Miot-Noirault E.

Mol Cancer Ther. 2016 Nov;15(11):2575-2585. Epub 2016 Aug 29.

13.

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy.

Viallard C, Chezal JM, Mishellany F, Ranchon-Cole I, Pereira B, Herbette A, Besse S, Boudhraa Z, Jacquemot N, Cayre A, Miot-Noirault E, Sun JS, Dutreix M, Degoul F.

Oncotarget. 2016 Mar 15;7(11):12927-36. doi: 10.18632/oncotarget.7340.

14.

Annexin A1 localization and its relevance to cancer.

Boudhraa Z, Bouchon B, Viallard C, D'Incan M, Degoul F.

Clin Sci (Lond). 2016 Feb;130(4):205-20. doi: 10.1042/CS20150415. Review.

PMID:
26769657
15.

Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma.

Billaud EM, Maisonial-Besset A, Rbah-Vidal L, Vidal A, Besse S, Béquignat JB, Decombat C, Degoul F, Audin L, Deloye JB, Dollé F, Kuhnast B, Madelmont JC, Tarrit S, Galmier MJ, Borel M, Auzeloux P, Miot-Noirault E, Chezal JM.

Eur J Med Chem. 2015 Mar 6;92:818-38. doi: 10.1016/j.ejmech.2015.01.034. Epub 2015 Jan 21.

PMID:
25637883
16.

[¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models.

Viallard C, Perrot Y, Boudhraa Z, Jouberton E, Miot-Noirault E, Bonnet M, Besse S, Mishellany F, Cayre A, Maigne L, Rbah-Vidal L, D'Incan M, Cachin F, Chezal JM, Degoul F.

Eur J Dermatol. 2015 Jan-Feb;25(1):29-35. doi: 10.1684/ejd.2014.2481.

PMID:
25548082
17.

Annexin A1 in primary tumors promotes melanoma dissemination.

Boudhraa Z, Rondepierre F, Ouchchane L, Kintossou R, Trzeciakiewicz A, Franck F, Kanitakis J, Labeille B, Joubert-Zakeyh J, Bouchon B, Perrot JL, Mansard S, Papon J, Dechelotte P, Chezal JM, Miot-Noirault E, Bonnet M, D'Incan M, Degoul F.

Clin Exp Metastasis. 2014 Oct;31(7):749-60. doi: 10.1007/s10585-014-9665-2. Epub 2014 Jul 6.

PMID:
24997993
18.

Small rigid platforms functionalization with quaternary ammonium: targeting extracellular matrix of chondrosarcoma.

Miot-Noirault E, Vidal A, Morlieras J, Bonazza P, Auzeloux P, Besse S, Dauplat MM, Peyrode C, Degoul F, Billotey C, Lux F, Rédini F, Tillement O, Chezal JM, Kryza D, Janier M.

Nanomedicine. 2014 Nov;10(8):1887-95. doi: 10.1016/j.nano.2014.06.011. Epub 2014 Jun 25.

PMID:
24972007
19.

Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.

Gardette M, Viallard C, Paillas S, Guerquin-Kern JL, Papon J, Moins N, Labarre P, Desbois N, Wong-Wah-Chung P, Palle S, Wu TD, Pouget JP, Miot-Noirault E, Chezal JM, Degoul F.

Invest New Drugs. 2014 Aug;32(4):587-97. doi: 10.1007/s10637-014-0086-5. Epub 2014 Apr 2.

PMID:
24691673
20.

(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.

Cachin F, Miot-Noirault E, Gillet B, Isnardi V, Labeille B, Payoux P, Meyer N, Cammilleri S, Gaudy C, Razzouk-Cadet M, Lacour JP, Granel-Brocard F, Tychyj C, Benbouzid F, Grange JD, Baulieu F, Kelly A, Merlin C, Mestas D, Gachon F, Chezal JM, Degoul F, D'Incan M.

J Nucl Med. 2014 Jan;55(1):15-22. doi: 10.2967/jnumed.113.123554. Epub 2013 Nov 21.

Supplemental Content

Loading ...
Support Center